Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Givastomig in Combination With Nivolumab and Chemotherapy in Advanced Gastric or Esophageal Cancer
NCT07432295Phase 2Recruiting
- Sponsor
- I-Mab
- Start
- Feb 2026
- Primary completion
- Mar 2030
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of givastomig in gastric cancer (GC), esophageal adenocarcinoma (EAC), gastroesophageal junction carcinoma (GEJ), sponsored by I-Mab. Started Feb 2026; status: recruiting.
02
Drugs
givastomig
03
Conditions
gastric cancer (GC)esophageal adenocarcinoma (EAC)gastroesophageal junction carcinoma (GEJ)
Beyond the preview
Go deeper on NCT07432295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07432295.